NEW ORLEANS — Medications in development would preserve muscle mass and augment fat loss when used in combination with glucagon-like peptide 1 (GLP-1) receptor agonists taken for weight loss. As drugs such as semaglutide (Wegovy) and the dual agonist glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Zepbound) are producing unprecedented degrees of weight loss in increasing numbers...
Tag: <span>GLP-1</span>
Post
GI Complications With GLP-1s for Weight Loss: Reexamining the Risks
Medscape Medical News > Conference News > DDW 2024 Damian McNamara, MA May 23, 2024 WASHINGTON, DC — In contrast with a previous study that found glucagon-like peptide 1 (GLP-1) receptor agonists associated with an increased risk for acute pancreatitis and bowel obstruction, a new retrospective study found no significant link to these complications. The...
Post
‘Obesity plus’: What’s next for GLP-1s?
Ayisha SharmaNews ReporterKatherine LewinNews ReporterNovo Nordisk and Eli Lilly are set to make billions of dollars each year off their GLP-1s, but patients and prescribers are still eager for improved drugs, citing GI side effects, muscle loss and weight gain after stopping treatment Add in the potential for drugs like Novo’s semaglutide (marketed as Wegovy...
Post
Why Do GLP-1 Drugs Stop Working, and What to Do About It?
Marilynn Larkin There’s no question that glucagon-like peptide 1 (GLP-1) agonists represent a major advance in the treatment of obesity for patients with or without diabetes. In clinical trials, participants lost 15%-20% of their body weight, depending on the drug. But studies also have shown that once people stop taking these drugs — either by...
Post
GLP-1 RAs for CVD: Are Cardiologists Ready?
The positive results from the SELECT trial for the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were hailed as ushering in a “new era for patients with obesity.” In the trial of overweight and obese patients with cardiovascular disease (CVD), but no diabetes, semaglutide showed meaningful reductions in cardiovascular death, myocardial infarction, and stroke compared with...
Post
Study identifies new concepts for GLP-1 action in the brain
by Lunenfeld-Tanenbaum Research Institute Graphical abstract. Credit: Cell Metabolism (2023). DOI: 10.1016/j.cmet.2023.11.009 Researcher Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named the 2023 breakthrough of the year by the Science Magazine. Not only have millions of people with type 2 diabetes benefitted from...
Post
GLP-1 Agonists and Suicide Risk: What Action Should Be Taken?
Boris Hansel, MD, PhDDISCLOSURES September 20, 2023 A statement from the European Medicines Agency (EMA) about semaglutide and, more generally, glucagon-like peptide 1 (GLP-1) agonists recently caused a stir. Could these medicines lead to patients taking their own lives?Medical Authorities Alert The EMA published a press release in early July 2023 to announce that a review is...
Post
Studies Implicate GLP-1 Agonists in Progression of Diabetic Retinopathy
Ellen Kurek August 03, 2023 SEATTLE — A family of blockbuster drugs for managing blood glucose — and now for promoting weight loss — has been linked to exacerbation of macular disease that frequently accompanies diabetes, new data show. Two studies presented at the 2023 annual meeting of the American Society of Retina Specialists have found that...
Post
Studies Implicate GLP-1 Agonists in Progression of Diabetic Retinopathy
Ellen Kurek August 03, 2023 SEATTLE — A family of blockbuster drugs for managing blood glucose — and now for promoting weight loss — has been linked to exacerbation of macular disease that frequently accompanies diabetes, new data show. Two studies presented at the 2023 annual meeting of the American Society of Retina Specialists have found that...
- 1
- 2